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Background
In the UK etanercept is licensed for use in children with
JIA age 4–17 years with active polyarticular disease which
has not fully responded to or the child has been intolerant
to methotrexate [1]. Studies have shown that the annual
cost of treatment with the addition of etanercept is only
slightly higher than prior costs because of reduced inpa-
tient and outpatient visits, reduction in need for other
treatments and reduction in loss of parental earnings [2].
The aim of this pilot study is to confirm that the cost of
etanercept in a UK cohort is off-set by the reduction in
intra-articular steroid injections.
Materials and methods
A pilot study was undertaken by random selection of 18
cases from the local etanercept database. The following
information was obtained by case note analysis: age, sex,
ILAR classification and joint injection episodes for 12
months pre and post commencement of etanercept.
Results
The mean age at start date of etanercept was 9.3 years
(range was 2.4 years to 16 years). 14 (78%) were girls and
4 (22%) were boys. The diagnosis was polyarticular (n =
7), extended oligoarticular (n = 8), persistent oligoarticu-
lar (n = 1), enthesitis related (n = 1) and unclassified (n =
1).
Pre etanercept there were 25 joint injection episodes in 15
patients and 9 episodes post-etanercept, representing a
reduction of 64%.
Conclusion
This pilot study showed a reduction in the need for intra-
articular steroid injections post etanercept. We are extend-
ing this analysis to our entire cohort and calculating the
cost implications.
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